Table II.
Parameter estimates of the final models.
| Model | Parameter | Estimate |
|---|---|---|
| A | Emax, % | -3.04 |
| ET50, week | 30.8 | |
| ωEmax | 1.360 | |
| ωET50 | 17.088 | |
| Ɛ | 0.062 | |
| B | Emax, % | -6.57 |
| ET50, week | 27.3 | |
| ωEmax | 2.773 | |
| ωET50 | 15.460 | |
| Ɛ | 0.100 | |
| C | Emax, % | -4.12 |
| ET50, week | 20.4 | |
| ωEmax | 0.585 | |
| ωET50 | 7.918 | |
| Ɛ | 0.327 | |
| D | Emax, % | -3.23 |
| ET50, week | 4.23 | |
| ωEmax | - | |
| ωET50 | 3.302 | |
| Ɛ | 0.010 |
Model A, patients treated with 2.5 mg/day dapagliflozin; model B, patients treated with 5 mg/day dapagliflozin; model C, patients treated with 10 mg/day dapagliflozin; D, patients treated with 20 mg/day dapagliflozin. Emax, maximal effect; ET50, treatment duration to reach half of the Emax; ωEmax, interstudy variability of Emax; ωET50, interstudy variability of ET50; Ɛ, residual error.